Neuren Pharmaceuticals (ASX:NEU) has reported a strong first-half performance for 2025, nearly doubling its profit after tax as royalties from its Rett syndrome therapy DAYBUE (trofinetide) continue to climb and its second drug candidate NNZ-2591 advances through late-stage development. …
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News